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Abstract 
Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third 
or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of 
data on eribulin efficacy in second line treatment. 
Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line 
eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. 
Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall 
survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 
months (95%CI: 1.7-5.3), respectively. We observed 8 (18.2%) partial responses and 10 (22.7%) patients had 
stable disease as best response. A longer PFS on previous first line treatment predicted a better OS (HR=0.87, 
95%CI: 0.77-0.99, p= 0.038) and a longer PFS on eribulin treatment (HR=0.92, 95%CI: 0.85-0.98, p=0.018). 
Progression free survival to eribulin was also favorably influenced by prior adjuvant chemotherapy (HR=0.44, 
95%CI: 0.22-0.88, p=0.02). Eribulin was generally well tolerated, with grade 3-4 adverse events being recorded 








Conclusions: The outcomes described for our cohort are consistent with those reported in the pivotal 
Study301 and subsequent observational studies. Further data from adequately-sized, ad hoc trials on eribulin 
use in second line for mTNBC are warranted to confirm our findings. 
Key words: eribulin mesylate, triple negative metastatic breast cancer, efficacy outcomes, toxicity outcomes, 
chemotherapy 
Introduction 
Approximately 15% of breast cancers are 
classified as triple-negative (TNBC), a subtype 
associated with aggressive clinical behavior and poor 
prognosis. Metastases in TNBC are described in about 
one-third of patients, with either recurrent or de novo 
metastatic disease [1]. 
Chemotherapy has long been considered the 
only active treatment for metastatic TNBC [2]. This 
latter scenario has recently changed with the advent 
of polyadenosine diphosphate-ribosepolymerase 
inhibitors (PARPis) for patients harboring BRCA 
mutations [3]. In addition, the contrasting evidence on 
the combination of chemotherapy and atezolizumab 
in patients with PD-L1 positive tumors intensely 
animates the scientific debate, due to the recently 
presented results from the IMpassion 130 and 131 trial 
[4,5]. 
Eribulin mesylate is a synthetic halichondrin B 
analog that inhibits the microtubule growth phase [6]. 
Among its non-mitotic mechanisms of action, it is 
worth mentioning its anti-angiogenetic effects and its 
ability to reverse epithelial-mesenchymal transition 
process [7,8]. Moreover, it was recently suggested an 
association between eribulin treatment and an 
increase in tumor-infiltrating lymphocytes (TILs), a 
relevant predictive and prognostic marker in triple 
negative (TN) disease [9]. Eribulin is approved for 
treatment of patients with advanced breast cancer 
who are refractory to other treatments. This is based 
on the results from the EMBRACE trial, wherein 
eribulin was compared to treatment of physician 
choice, and from the Study 301, which evaluated 
eribulin in comparison with capecitabine [10,11]. In 
specific regard to eribulin activity in TNBC, a pooled 
analysis including patients of the EMBRACE and 301 
trials showed a survival benefit for patients receiving 
eribulin versus control or capecitabine [12]. However, 
only the 301 Study enrolled TNBC patients receiving 
eribulin in second-line [13]. 
Herein we present our work aimed at 
investigating second-line eribulin efficacy in mTNBC 
in a historical cohort of patients treated at 14 Italian 
cancer centres. 
Methods 
The TETRIS trial is a multicenter retrospective 
study which was designed to assess the efficacy of 
eribulin as second line of treatment in patients 
affected by mTNBC. The study was conducted in full 
accordance with the guidelines for Good Clinical 
Practice and the Declaration of Helsinki, and was 
approved by the institutional ethics committees of 
each center. Overall, 14 cancer centers adhered to our 
study. Written informed consent was obtained from 
all patients who remained alive at the time of trial 
approval. Patients were deemed suitable for inclusion 
in the TETRIS trial if diagnosed with mTNBC, and 
having received at least one cycle of eribulin (1.23 
mg/m2) following failure of a first line chemotherapy. 
Eribulin had to be delivered between January 2013 
and September 2019, since a minimum 12-month 
follow up was required. In addition, data availability 
was required concerning key patient- and disease 
clinical-pathological variables, along with treatment 
outcomes. Eribulin treatment was delivered until 
disease progression, unacceptable toxicity or patient 
refusal, and efficacy was evaluated according to 
Response Evaluation Criteria in Solid Tumors (v. 1.1). 
Adverse events were recorded and graded according 
to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (v.4.0). 
The primary objectives of the study were 
progression free survival (PFS), and overall survival 
(OS). Secondary endpoints included objective 
response and safety outcomes. Explorative analyses 
for potential clinical-pathological predictors of 
efficacy were also performed. 
Descriptive statistics were used to characterize 
the study sample. Performance status was assessed 
according to the Eastern Cooperative Oncology 
Group (ECOG PS) prior to and following eribulin 
treatment and compared by Wilcoxon test. The 
Kaplan-Meier method and log-rank test were used to 
estimate survival and compare the inherent data 
across subgroups defined upon clinically and 
molecularly relevant variables. Univariate and 
multivariate Cox proportional hazards regression 
models were developed/built to evaluate associations 
of clinical-pathologic features with PFS and OS. 
Multivariate analysis was carried out including only 
variables testing significant in univariate analysis. The 
SPSS software (SPSS version 21.0, SPSS Inc., Chicago, 
IL) was used for all statistical evaluations. The 
significance levels for all performed tests was set at 
p<0.05. 




Table 1. Baseline characteristics of the TETRIS participants 
(N:44) 
Patients’ Characteristics N (%) 
Age in years, median (range) 51 (35-81) 
Menopausal status at diagnosis  
Premenopausal 17 (38.6) 
Postmenopausal 27 (61.4) 
Surgery on primary tumor  
Yes 23 (52.3) 
No 21 (47.7) 
Histotype  
Ductal carcinoma 42 (95.5) 
Lobular carcinoma 1 (2.3) 
Other 1 (2.3) 
Triple-negative cancer at diagnosis  
Yes 40 (90.9) 
No 4 (9.1) 
Tumor grade  
2 3 (6.8) 
3 40 (90.9) 
Missing 1 (2.3) 
BRCA 1/2 mutation  
Yes 1 (2.3) 
No 26 (59.1) 
Unknown 17 (38.6) 
Neoadjuvant chemotherapy 10 (22.7) 
(Neo)adjuvant Carboplatin 2 (4.5) 
Adjuvant chemotherapy 25 (56.8) 
Adjuvant Capecitabine 3 (6.8) 
Metastasis at diagnosis  
Yes 5 (11.4) 
No 39 (88.6) 
Number of metastatic sites  
1 13 (29.5) 
2 20 (45.5) 
>2 11 (25.0) 
Pattern of metastatic involvement  
Visceral 22 (50.0) 
Bone-only 2 (4.5) 
Other 20 (45.5) 
First-line therapy  
Paclitaxel 3 (6.8) 
Paclitaxel/Bevacizumab 14 (31.8) 
Anthracyclines 2 (4.5) 
Capecitabine 3 (6.8) 
Platinum Salts 11 (25) 
Other 11 (25) 
Pretreatment (neo-adjuvant plus first-line)  
Taxanes 38 (86.4) 
Anthracyclines 27 (61.4) 
Carboplatin 14 (31.8) 
Capecitabine 6 (13.6) 
Two agents 19 (43.2) 
Three agents 12 (27.3) 
ECOG PS at Eribulin start  
0 17 (38.6) 
1 24 (54.5) 
2 2 (4.5) 
Unknown 1 (2.3) 
Third line treatment  
None 18 (40.9) 
Nab-paclitaxel 11 (25) 
Gemcitabine + Vinorelbine 3 (6.8) 
Carboplatin + Gemcitabine 3 (6.8) 
Carboplatin 1 (2.3) 
Gemcitabine 1 (2.3) 
Capecitabine 3 (6.8) 
Other 4 (9.1) 
Fourth line treatment  
Platinum (Cis/Carbo) 2 (4.5) 
Capecitabine 2 (4.5) 
Anthracyclines 1 (2.3) 
Other 1 (2.3) 
Results 
Forty-four patients met the study inclusion 
criteria. Main patient and tumor characteristics are 
shown in Table 1. Median PFS to the previous first 
line treatment was 7.0 months (range: 1.0-21.0), as 
calculated by the Kaplan Meier product limit (Suppl 
Table S1). The main clinical outcomes of eribulin 
treatment are listed in Suppl Table S2. Median PFS on 
second line eribulin was 3.5 months (range: 1.7-5.3), 
with a one year-PFS rate of 16.7%. Median OS was 
11.9 months (range: 8.4-15.5), with OS rates at 1-year 
and 2-years of 43.0% and 12.7%, respectively (Figure 
1A and 1B). Second line eribulin did not yield any 
complete response (CR). However, 18.2% of partial 
responses (PR) and 22.7% of stable diseases (SD) were 
recorded. 
The comparison of survival curves showed that 
having received a previous adjuvant treatment 
predicted a better PFS on second line eribulin with 
respect to not having received it (p=0.02, log-rank test) 
(Fig. 2). Also, PFS on first line treatment impacted PFS 
to second line eribulin. As shown in Suppl Figure 1, 
the survival curve for PFS on eribulin was more 
favorable for those patients who had experienced a 
PFS longer than 10 months on the previous line of 
treatment, with PFS rates on eribulin at 12 months of 
43.0% vs. 9.8% (p=0.03, log-rank test). Interestingly, 
difference in ECOG PS at eribulin starting, namely, 0 
compared to 1-2, did not influence survival (p= 0.33, 
log-rank test). Univariate analysis (Suppl Table S3) 
confirmed that only adjuvant chemotherapy and first 
line PFS had a significant effect on eribulin PFS. 
Adjuvant treatment and PFS on first line maintained a 
significant effect on eribulin PFS in multivariate 
analysis. Likewise, PFS to first line treatment was 
positively related to a longer PFS on eribulin 
treatment, both when it was considered as a 
continuous variable or as a categorical variable with a 
10 months cut-off value (Suppl Table S4). 
Survival curves for OS only differed when 
stratifying patients according to PFS duration on first 
line and ECOG PS at eribulin start (Suppl Fig. 1B and. 
2). In more detail, patients whose PFS on first line > 6 
months showed a better survival with respect to those 
whose PFS was ≤ 6 months, with 12-month OS rates 
being 58.7% vs. 26.8%, and 24-month OS rates being 
14.0% vs. 8.9% (p= 0.02, log-rank test), respectively. 
Similarly, patients with an ECOG PS at eribulin start 
of 0 had a better OS compared to those with ECOG PS 
1-2, with respective OS rates of 63.6% vs. 26.7% at 12 
months, and 27.3% vs. 0.0% at 24 months (p= 0.003, 
log-rank test). In the univariate model (Suppl Table 
S5), the variables associated with a lower risk of death 
from eribulin start were the following: age, longer PFS 
on first line, PFS on first line > 6 months, and a better 




ECOG PS at eribulin start. However, in multivariate 
analysis, only a longer PFS on first line remained as an 
independent predictor of better OS from eribulin start. 
Values on pre-and post eribulin ECOG PS were 
available for 41 patients. Its variation following 
eribulin treatment (Table 2) resulted statistically 
significant by using Wilcoxon test (p= 0.0001). 
 
Table 2. ECOG PS at eribulin start vs eribulin end. The TETRIS 
study (N:44) 
ECOG PS at eribulin start ECOG PS at eribulin end Total 
0 1 2 3 4 
ECOG PS 0 6 8 2   16 
ECOG PS 1  10 9 4  23 
ECOG PS 2   1  1 2 
Total 6 18 12 4 1 41 
*Wilcoxon test: p<0.0001; 
ECOG PS: Eastern cooperative oncology group performance status. 
 
 
Table 3. Toxicity profile of the TETRIS study participants (N:44) 
 All grades, N (%) Grade 3, N (%) Grade 4, N (%) 
Hematological    
Neutropenia 20 (45.5) 2 (4.5) 0 
Anemia 18 (40.9) 1 (2.3) 0 
Thrombocytopenia 6 (13.6) 1 (2.3) 1 (2.3) 
Non-hematological    
Fatigue 34 (77.3) 3 (6.8) 0 
Peripheralneuropathy 22 (50) 1 (2.3) 0 
Nausea/vomiting 20 (45.5) 0 0 
Diarrhea 5 (11.4) 0 0 
AST/ALT alterations 9 (20.4) 0 0 
 
 
Eribulin administration was generally safe, and 
no toxic deaths occurred. Two patients (4.5%) 
discontinued treatment for gastrointestinal toxicity 
and neurotoxicity, respectively. The most frequent 
toxicities were fatigue (all grades, 33 patients, 77.3%) 
and peripheral neuropathy (all grades, 22; 50.0%) 
(Table 3). Grade 3/4 adverse events (AEs) were 
recorded in 7 patients (15.9%) and were mostly 
related to fatigue (3 patients, 6.8%) and neutropenia (2 
patients, 4.5%). 
In the whole cohort, 26 patients (59.1%) received 
a third line of treatment, which was more often 
represented by nab-paclitaxel or a gemcitabine-based 
regimen (Table 1). 
 
 
Figure 2. PFS by prior adjuvant treatment (Chemotherapy: yes vs no). Adj.: adjuvant, 
PFS: Progression Free Survival. N: 44 patients. 
 
Figure 3. Second line (Eribulin) PFS by length of first line PFS (≤10 vs >10 months). 
PFS: Progression Free Survival, m: months. N: 44 patients. 
 
Figure 1. Second line eribulin treatment: 12-months PFS (A) and 12- and 24-months OS (B). PFS: Progression Free Survival. OS: Overall Survival. N: 44 patients. 
 





The present study mainly reports on the efficacy 
of eribulin administered as second-line therapy in 
mTNBC patients. Overall, eribulin treatment in our 
cohort was safe, with manageable toxicities. To our 
knowledge, evidence from literature concerning 
eribulin use in mTNBC as second-line treatment is 
lacking, with the majority of data being from 
retrospective studies [14-19]. In the pooled analysis of 
the EMBRACE trial and Study 301, the PFS on eribulin 
from TNBC patients was 2.8 months, but most of these 
patients had received more than 1 previous 
chemotherapy line [12]. Overall, our findings are 
consistent with results from randomized clinical trials 
(RCTs), thus confirming the activity of eribulin in the 
mTNBC subset even in a non-selected patient 
population. 
This study has some limitations. In first place, 
the topic of interest was addressed using a 
retrospective design. Heterogeneity in the study 
population characteristics may represent a further 
focus of discussion. Further critiques may be fueled 
by the study sample size, which appears somewhat 
limited. This may be at least partly explained by the 
relatively low representation of TNBC among the 
molecularly defined breast cancer subtypes. 
Our study also has some relevant strengths. The 
topic of choice is extremely timely and of vivid 
interest to a cancer research agenda. Indeed, TNBC 
patients represent the breast cancer subgroup with the 
highest need for innovative treatment options, as 
witnessed by the recent efforts of the scientific 
community aimed at broadening the available 
therapeutic armamentarium. The critical 
interpretation of the data herein presented, 
notwithstanding the limitations stemming from the 
retrospective approach, adds a block of evidence to 
current knowledge from the pivotal eribulin RCTs 
and other prior observational studies. In fact, to the 
best of our knowledge, in none of the prior studies of 
eribulin in mTNBC, independently on the study 
design, the authors have specifically focused on the 
exclusive use of this agent in second line. 
In conclusion, our study confirms the role of 
eribulin as an efficacious and safe option of treatment 
in the landscape of mTNBC, and an early inclusion in 
the continuum of treatment strategies could increase 
the inherent clinical benefits. 
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